US tries to buy exclusive German firm’s low-dose coronavirus vaccine research

GERMANY (HRNW) – Germany is trying to stop Washington from persuading a local company seeking a coronavirus vaccine to move its research to the United States, prompting German politicians to insist no country should have a monopoly on any future vaccine.

Germany’s Health Ministry confirmed a report in newspaper Welt am Sonntag, which said President Donald Trump had offered funds to lure the company CureVac to the United States, and the German government was making counter-offers to tempt it to stay.

“The German government is very interested in ensuring that vaccines and active substances against the new coronavirus are also developed in Germany and Europe,” the newspaper quoted a Health Ministry official as saying. “In this regard, the government is in intensive exchange with the company CureVac.” The German Health Ministry confirmed the report to Reuters.

Welt am Sonntag quoted an unidentified German government source as saying Trump was trying to secure the scientists’ work exclusively, and would do anything to get a vaccine for the United States, “but only for the United States.”